Liquid Glucagon: Improving Utilisation for Emergency Treatment of Severe Hypoglycemia

Arecor是开发稳定的治疗药物配方的世界领先者，拥有旨在治疗糖尿病的差异化产品概念的内部开发计划。Arecor制定了坚实的计划，将这些产品概念发展到第一阶段临床概念验证和随后的资产许可。其中一个产品概念是液体胰高血糖素，既可用于紧急情况，也可用作双激素泵的关键组件。Arecor已经开发出胰高血糖素的原型液体配方，显示出足够的稳定性，可以用于可行的商业产品。在InnovateUK的关键支持下，Arecor正在通过临床前开发进一步优化这项资产，以确保与选定的给药装置、毒理学研究、正式的稳定性研究和经过验证的药代动力学研究的兼容性。在这项研究之后，Arecor将准备进入第一阶段人体试验。稳定的液体高血糖素产品将通过消除对目前市场上销售的冻干产品的复杂重组的需要，改变使用高血糖素紧急治疗严重低血糖发作的方式。此外，人们认识到液体高血糖素作为双激素泵的关键组件的必要性，该产品也将解决这一问题。

Arecor is a world leader in developing stable formulations of therapeutics, with in-house development programmes aimed at differentiated product concepts in diabetes. Arecor has solid plans for developing those product concepts to Phase I clinical proof-of-concept and subsequent licensing of the assets. One of the product concepts is liquid glucagon, both for emergency use and as a critical component for a bihormonal pump. Arecor has developed prototype liquid formulations of glucagon showing sufficient stability for a viable commercial product. With the critical support from InnovateUK, Arecor is progressing this asset through pre-clinical development by performing further optimisation to ensure compatibility with a selected delivery device, toxicology studies, formal stability studies and validated pharmacokinetic studies. Following this study, Arecor will be ready to move into Phase I human trial. Stable liquid glucagon product will transform the way glucagon is used for emergency treatment of severe hypoglycaemia episodes by removing the need for a complex reconstitution of the currently marketed lyophilised products. In addition, there is a recognised need for liquid glucagon as a critical component of bihormonal pumps that will also be addressed by this product.